Seres Therapeutics Inc (MCRB) - News Archive

: Seres Therapeutics, a pioneering company in microbiome therapeutics, has announced the receipt of a significant financial boost from CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) with...

Exploring the Therapeutic Potential of SER-155: Insights from Biomarker Data and Economic Challenges of Seres Therapeutics The landscape of post-transplant care has continuously evolved, with recent advancements focusin...

In a landmark strategic move, Seres Therapeutics, Inc. (Nasdaq: MCRB), headquartered in Cambridge, Massachusetts, has successfully completed the sale of its VOWST business to Societé des Produits Nestlé S.A. a subsidiar...

Seres Therapeutics Gains Stockholder Endorsement for VOWST Sale to Nestlé Health Science, Anticipated Closure by Month-EndIn a strategic move that underscores the evolving landscape of biotherapeutics, Seres Therapeutic...

Seres Therapeutics has reported promising findings from its Phase 1b placebo-controlled trial evaluating SER-155 in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study demonstra...

Seres Therapeutics, a pioneering biotechnology company focused on developing microbiome therapeutics, has recently announced a significant financial move through an asset purchase agreement with Nestlé Health Science. T...

Seres Therapeutics Grants Inducement Equity to New Employee, Boosting Future PotentialCAMBRIDGE, Mass, June 07, 2024 - Seres Therapeutics, a renowned microbiome therapeutics company, recently announced the granting of i...

Seres Therapeutics, a leading microbiome therapeutics company, has announced its plans to secure capital infusions that will enable the company to retire its debt completely and extend its cash runway into the fourth qu...